中國金屬利用(01636.HK)擬溢價約121.4%發行1.72億股以抵銷未償還負債
格隆匯8月28日丨中國金屬利用(01636.HK)發佈公吿,於2021年10月13日,公司與認購方富康國際有限公司訂立認購協議,據此,公司有條件地同意發行而認購方有條件地同意按認購價每股認購股份0.465港元(認購價較於2021年10月12日收市價每股0.210港元溢價約121.4%)認購1.72億股,相當於公司現有已發行股本約5.24%;及經發行擴大已發行股本約4.98%。
認購方應付公司的認購代價8000萬港元應於完成後按等額基準抵銷未償還負債的等值金額。因此,公司將不會從認購事項收到任何現金所得款項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.